Evidence Trace, complete trial record
In plain terms
In plain terms: Lactoferrin shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.
Lactoferrin
C
Limited: small, mixed or unreplicated trials
The endpoint this grade is based on: self_report, Graded by use. Symptom scores in healthy adults: Grade C, two trials from the maker of the product, one positive on symptom scores and one that shortened illness by about a day without changing how many people got sick. Preventing respiratory infection in adults: Grade D, tested without benefit in the maker's larger trial, an independent COVID-prevention trial and a pooled analysis.
The evidence as the record states it
Oda et al. (Nutrients, 2023; PMID 37764743): 157 healthy adults, bovine lactoferrin 200 mg/day for 12 weeks; respiratory and systemic symptom scores and plasmacytoid dendritic-cell activity improved against placebo in the full analysis set of 145, with more dropouts on lactoferrin (10) than placebo (2). Funded by the maker, which supplied the product; five of nine authors are its employees. Oda et al. (J Microbiol Immunol Infect, 2021; PMID 32151562): the same sponsor's larger trial, 310 adults randomized to placebo, 200 or 600 mg for 12 weeks in summer; illness duration shorter (2.0 against 3.0 days) and no difference in the prevalence of infection or in immune markers; five authors are the maker's employees. Independent: Navarro et al. (Biometals, 2023; PMID 36474100), 209 Peruvian health workers, 600 mg/day for 90 days, SARS-CoV-2 infection 10.6 against 8.6 percent, no difference, stopped early when vaccines arrived. Berthon et al. (Adv Nutr, 2022; PMID 35481594): systematic review and meta-analysis, 25 studies; respiratory infection incidence lower in infants and children (OR 0.78) and not in adults (OR 1.00, 95% CI 0.76 to 1.32); IL-6 lower in adults, CRP unchanged. Razak et al. (Am J Perinatol, 2021; PMID 31529448): preterm-infant late-onset sepsis meta-analysis, separate population, context only. Grade C on symptom scores from the maker's trials; D on Route 2 for preventing infection in adults.
PMID 37764743 PMID 31529448 PMID 32151562 PMID 35481594 PMID 36474100
Evidence by specific use
Respiratory and systemic symptom scores in healthy adults
Grade C
Oda et al. (Nutrients, 2023; PMID 37764743): symptom scores lower on 200 mg/day over 12 weeks in 145 analyzed adults, with more dropouts on lactoferrin than placebo. Oda et al. (2021; PMID 32151562): the same sponsor, site and lead author, 310 adults; illness duration about a day shorter, no difference in how many got sick. Two trials from one maker, not independent replication, on self-reported scores: C.
PMID 37764743 PMID 32151562
Prevention of respiratory infection in adults
Grade D
Tested and no benefit in adults: the maker's 310-person trial found no difference in infection prevalence (Oda et al., 2021; PMID 32151562), an independent 90-day trial in health workers found no reduction in SARS-CoV-2 infection (Navarro et al., 2023; PMID 36474100), and the pooled adult odds ratio is 1.00 (Berthon et al., 2022; PMID 35481594). The reduction in infants and children in the same pooling is a different population and is not graded here.
PMID 32151562 PMID 36474100 PMID 35481594
Why Grade C and not Grade B
Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.
What this grade covers and what it does not
Grade C, the record's best use: respiratory and systemic symptom scores in healthy adults, on two trials from the product's maker. Oda et al. (Nutrients, 2023; PMID 37764743) found symptom scores lower on 200 mg/day over 12 weeks, in a full analysis set with more dropouts on lactoferrin than placebo; Oda et al. (2021; PMID 32151562), the same sponsor and lead author, found illness about a day shorter and no difference in how many people got sick. Maker-run self-report findings without independent replication are C, and the funding is stated beside the letter. PREVENTING INFECTION IN ADULTS IS D ON ROUTE 2: the maker's own larger trial found no difference in prevalence, an independent trial in health workers found no reduction in SARS-CoV-2 infection (Navarro et al., 2023; PMID 36474100), and the pooled adult odds ratio is 1.00 (Berthon et al., 2022; PMID 35481594). WHAT THIS GRADE DOES NOT COVER: infants and children, where the pooled analysis found fewer infections; preterm infants and late-onset sepsis (Razak et al., 2021; PMID 31529448), a separate population; iron status; and the dendritic-cell activation markers, which are mechanism rather than outcome.
What would move this grade
A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.
How to track whether this is working
Serum iron and ferritin for iron-metabolism applications at baseline and 8 weeks. For immune applications, track IgA levels and frequency of upper respiratory infections over a 3-month period. For gut health, track inflammatory markers (CRP, calprotectin) at baseline and 12 weeks.